170 related articles for article (PubMed ID: 32781690)
1. Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells.
Passariello M; Vetrei C; Sasso E; Froechlich G; Gentile C; D'Alise AM; Zambrano N; Scarselli E; Nicosia A; De Lorenzo C
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32781690
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments.
Vetrei C; Passariello M; Froechlich G; Rapuano Lembo R; Zambrano N; De Lorenzo C
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34201082
[TBL] [Abstract][Full Text] [Related]
3. Ipilimumab and Its Derived EGFR Aptamer-Based Conjugate Induce Efficient NK Cell Activation against Cancer Cells.
Passariello M; Camorani S; Vetrei C; Ricci S; Cerchia L; De Lorenzo C
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32024070
[TBL] [Abstract][Full Text] [Related]
4. New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC.
Lembo RR; Manna L; Froechlich G; Sasso E; Passariello M; De Lorenzo C
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358708
[TBL] [Abstract][Full Text] [Related]
5. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
Du X; Tang F; Liu M; Su J; Zhang Y; Wu W; Devenport M; Lazarski CA; Zhang P; Wang X; Ye P; Wang C; Hwang E; Zhu T; Xu T; Zheng P; Liu Y
Cell Res; 2018 Apr; 28(4):416-432. PubMed ID: 29472691
[TBL] [Abstract][Full Text] [Related]
6. A mathematical modelling tool for unravelling the antibody-mediated effects on CTLA-4 interactions.
Ganesan A; Arulraj T; Choulli T; Barakat KH
BMC Med Inform Decis Mak; 2018 Jun; 18(1):37. PubMed ID: 29890992
[TBL] [Abstract][Full Text] [Related]
7. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.
Ha D; Tanaka A; Kibayashi T; Tanemura A; Sugiyama D; Wing JB; Lim EL; Teng KWW; Adeegbe D; Newell EW; Katayama I; Nishikawa H; Sakaguchi S
Proc Natl Acad Sci U S A; 2019 Jan; 116(2):609-618. PubMed ID: 30587582
[TBL] [Abstract][Full Text] [Related]
8. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.
Fong L; Small EJ
J Clin Oncol; 2008 Nov; 26(32):5275-83. PubMed ID: 18838703
[TBL] [Abstract][Full Text] [Related]
9. CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis.
Jie HB; Schuler PJ; Lee SC; Srivastava RM; Argiris A; Ferrone S; Whiteside TL; Ferris RL
Cancer Res; 2015 Jun; 75(11):2200-10. PubMed ID: 25832655
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.
Ramagopal UA; Liu W; Garrett-Thomson SC; Bonanno JB; Yan Q; Srinivasan M; Wong SC; Bell A; Mankikar S; Rangan VS; Deshpande S; Korman AJ; Almo SC
Proc Natl Acad Sci U S A; 2017 May; 114(21):E4223-E4232. PubMed ID: 28484017
[TBL] [Abstract][Full Text] [Related]
11. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.
O'Day SJ; Hamid O; Urba WJ
Cancer; 2007 Dec; 110(12):2614-27. PubMed ID: 18000991
[TBL] [Abstract][Full Text] [Related]
12. CTLA-4 is expressed by activated mouse NK cells and inhibits NK Cell IFN-γ production in response to mature dendritic cells.
Stojanovic A; Fiegler N; Brunner-Weinzierl M; Cerwenka A
J Immunol; 2014 May; 192(9):4184-91. PubMed ID: 24688023
[TBL] [Abstract][Full Text] [Related]
13. Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation.
Vandenborre K; Van Gool SW; Kasran A; Ceuppens JL; Boogaerts MA; Vandenberghe P
Immunology; 1999 Nov; 98(3):413-21. PubMed ID: 10583602
[TBL] [Abstract][Full Text] [Related]
14. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.
Linsley PS; Greene JL; Tan P; Bradshaw J; Ledbetter JA; Anasetti C; Damle NK
J Exp Med; 1992 Dec; 176(6):1595-604. PubMed ID: 1334116
[TBL] [Abstract][Full Text] [Related]
15. ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer.
Ehlerding EB; England CG; Majewski RL; Valdovinos HF; Jiang D; Liu G; McNeel DG; Nickles RJ; Cai W
Mol Pharm; 2017 May; 14(5):1782-1789. PubMed ID: 28388076
[TBL] [Abstract][Full Text] [Related]
16. Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy.
Zhao Y; Yang W; Huang Y; Cui R; Li X; Li B
Cell Physiol Biochem; 2018; 47(2):721-734. PubMed ID: 29794465
[TBL] [Abstract][Full Text] [Related]
17. A DNA vaccine against cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) prevents tumor growth.
Lan KH; Liu YC; Shih YS; Tsaid CL; Yen SH; Lan KL
Biochem Biophys Res Commun; 2013 Oct; 440(2):222-8. PubMed ID: 24041689
[TBL] [Abstract][Full Text] [Related]
18. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3
Sharma A; Subudhi SK; Blando J; Scutti J; Vence L; Wargo J; Allison JP; Ribas A; Sharma P
Clin Cancer Res; 2019 Feb; 25(4):1233-1238. PubMed ID: 30054281
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the high-affinity anti-CTLA-4 monoclonal antibody JS007 for immune checkpoint therapy of cancer.
Guan J; Liu H; Chai Y; Yu J; Yao J; Wang J; Pan Z; Zhang J; Zhou Y; Liu H; Yao S; Qi J; Feng H; Gao GF; Wang Q; Shi Y; Tan S
MAbs; 2023; 15(1):2153409. PubMed ID: 36511654
[TBL] [Abstract][Full Text] [Related]
20. Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.
Sanseviero E; O'Brien EM; Karras JR; Shabaneh TB; Aksoy BA; Xu W; Zheng C; Yin X; Xu X; Karakousis GC; Amaravadi RK; Nam B; Turk MJ; Hammerbacher J; Rubinstein MP; Schuchter LM; Mitchell TC; Liu Q; Stone EL
Cancer Immunol Res; 2019 Aug; 7(8):1371-1380. PubMed ID: 31239316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
